Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.03
- Piotroski Score 0.00
- Grade Outperform
- Symbol (SYN)
- Company Synthetic Biologics, Inc.
- Price $1.02
- Changes Percentage (0.99%)
- Change $0.01
- Day Low $0.97
- Day High $1.02
- Year High $4.55
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.12
- Trailing P/E Ratio -8.5
- Forward P/E Ratio -8.5
- P/E Growth -8.5
- Net Income $-19,685,000
Income Statement
Quarterly
Annual
Latest News of SYN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Those who invested in EcoSynthetix (TSE:ECO) five years ago are up 41%
EcoSynthetix Inc. stock price rose 41% in 5 years, below market average. Despite revenue decline, the 7% annual return is decent. Insiders buying shares is positive, but consider other growth trends b...
By Yahoo! Finance | 17 hours ago -
Black Cat Syndicate (ASX:BC8) shareholder returns have been impressive, earning 119% in 1 year
Investing carries risks, but successful picks can yield over 100% returns. Black Cat Syndicate's share price doubled in a year due to 158% revenue growth. Although caution is advised, the positive sen...
By Yahoo! Finance | 2 days ago -
5 signs you have eldest-daughter syndrome, from a therapist who was the oldest of 6 kids
Eldest daughters often face pressure and perfectionism, leading to traits like overachievement and self-reliance. Therapist Annie Wright discusses how "eldest-daughter syndrome" affects their relation...
By Business Insider | 2 days ago
